Jesús F Bermejo Martín, MD PhD

He leads a translational research group working at the National Health System in Valladolid, Spain, devoted to understand sepsis physiopathology and to identify biomarkers to predict, early detect and improve clinical management of this disease. The group accounts with regular financial support from the "Instituto de Salud Carlos III", and "Castilla y León Health Council", Spain, and collaborates with top international biotech companies such as Thermo Fisher or Inflammatix.

Focus of research: in addition to biomarker discovery, the main interest of the group is studying the interaction between the immune system and the vascular endothelium in patients with chronic diseases as predisposing / triggering factor for Sepsis.

He is one of the EGIS management coordinators.

Jesús F Bermejo Martín, MD PhD
Jesús F Bermejo Martín

Prof. Dr. Ignacio Rubio

Biochemist by training, he leads the experimental unit for sepsis research at the Clinic for Anesthesiology and Intensive Care of the University Hospital in Jena, Germany.

His major research focus is the role of T-cells and monocytes in the course of the host response to sepsis.

He is the second EGIS management coordinator.

Prof. Dr. Ignacio Rubio
Ignacio Rubio

Raquel Almansa, PhD

Raquel Almansa is post-doctoral researcher working in the Biosepsis group at the National Health System in Spain. She is also associate professor of Genetics and Cell Biology at the School of Medicine, University of Valladolid.

Raquel's research interest is focused in understanding host's immune response to infection, the interaction between the immune system and the vascular endothelium and to identify host biomarkers to predict, detect and improve management of infectious diseases at pre-hospital and hospital setting.

Raquel Almansa
Raquel Almansa

Prof. Dr. Michael Bauer

Michael Bauer is professor and chair for Anesthesiology and Critical Care Medicine as well as spokesman of the Integrated Research and Treatment Center for Sepsis Control and Care (CSCC) at Jena University Hospital.

Research interests in sepsis are

  • mechanisms of multi-organ failure, especially the roles of kinases and other signaling events;
  • nanomedical strategies for targeted delivery of kinase inhibitors and siRNAs as well as
  • heme and its degradation products in sepsis and organ failure.


Prof. Dr. M. Bauer
Michael Bauer

Prof. Dr. Frank M. Brunkhorst, MD

Director of the Center for Clinical Studies and Full Professor for clinical sepsis research at the Jena University Hospital.

Research fields:
  • Epidemiology of infectious diseases and sepsis,
  • Diagnosis and prevention of infectious diseases and sepsis,
  • Antimicrobial therapy in infectious diseases and sepsis
  • Supportive and adjunctive therapy of Sepsis.
Prof. Dr. F. Brunkhorst
Frank M. Brunkhorst

Sara Cajander, MD, PhD, Adjunct Assoc. Prof.

Clinician-Scientist specialized in Infectious Diseases, Senior Consultant Physician at the Department of Infectious Diseases, Örebro University Hospital, and Adjunct Associate Professor at the Faculty of Medicine and Health, Örebro University, Sweden.
Dr Cajander has a special research interest in the scientific field of sepsis immunology and she collaborates with research groups at the Karolinska Institute, Stockholm, Sweden. She is a member of the national expert committee responsible for the Swedish national clinical guidelines for evidence-based sepsis management. Based on her work as a Consultant for Infectious Diseases in the Intensive Care Unit, she keeps an updated view on the clinical relevance of sepsis research and future diagnostics.

Sara Cajander
Sara Cajander

Prof. Dr. Jean-Marc Cavaillon

  • Reprogramming of immune cells during sepsis.
  • Biomarkers for diagnosis of Sepsis.
  • Redefining appropriate animal models.

"Science has no borders because knowledge belongs to humanity" (Louis Pasteur)


Jean-Marc Cavaillon
Jean-Marc Cavaillon

Ricard Ferrer MD, PhD

Dr. Ricard Ferrer is Head of the Intensive Care Department at Vall d’Hebron Hospital in Barcelona, Spain. He graduated in 1992 from the University of Barcelona, Medical School and pursued his specialisation in Intensive Care from 1994 to 1998 and his PhD title in 2010 from the Universitat Autonoma de Barcelona.
Prof. Ferrer holds several positions at a numerous intensive care societies: He is president of the Spanish Society of Intensive Care (SEMICYUC) and he is member of the steering committee of the Surviving Sepsis Campaign. In the ESICM, he is the Chairman of the Systemic Inflammation and Sepsis section, organizer of the NEXT fellowship in Infectious Diseases in Barcelona and member of the Council.

Ricard Ferrer
Ricard Ferrer

Prof. Dr. Stefanie B. Flohé, PhD

My main interest is the development of immunosuppression during sepsis and after severe injury in mice and men with emphasis on the function of dendritic cells and natural killer cells.

I support EGIS since it represents a unique platform for scientific and clinical exchange that hopefully will boost the understanding of sepsis and the development of novel therapies.

Stefanie B. Flohé, PhD
Stefanie B. Flohé

Alberto García-Salido, MD, PhD

Alberto García-Salido is specialist in pediatrics with expertise in Pediatric Intensive Care. Nowadays he carries out basic research at the Niño Jesús University Children's Hospital, Madrid. He has especial interest in the clinical application of flow cytometry in infectious diseases and inflammatory diseases with main focus on the innate immunity. Its investigations are developed in critical and not critical children focused in diagnosis, monitorization and to anticipate the clinical course.

For further details:

Alberto García-Salido
Alberto García-Salido

Evangelos J. Giamarellos-Bourboulis, MD, PhD, Assoc. Prof.

  • Co-ordinator of the Hellenic Sepsis Study Group that holds a large clinical database and biobank of patients.
  • Sponsor of the PROVIDE trial with Prof. M. G. Netea ( registration NCT03332225) that is the first randomized clinical trial aiming to the impact of immunotherapy according to personalized needs.
  • Main research interest: modulation of innate immune responses in sepsis


Evangelos J. Giamarellos-Bourboulis, MD, PhD
Evangelos J. Giamarellos-Bourboulis

Matthijs Kox, PhD, Assoc. Prof.

Matthijs Kox is assistant professor at the department of Intensive Care Medicine of the Radboud university medical centre in Nijmegen, the Netherlands.

He supervises a team of 10 PhD candidates and a research technician, all of whom perform translational studies into modulation of the immune response, with a focus on sepsis. Furthermore, he pioneered studies into voluntary modulation of the sympathetic nervous system and immune response using a behavioral intervention developed by “Iceman” Wim Hof.

For further details; please see:


Matthijs Kox
Matthijs Kox

PD Dr. Gunnar Lachmann, MD

Clinician Scientist at the Department of Anesthesiology and Operative Intensive Care Medicine, Charité – Universitätsmedizin Berlin and coordinator of the HEMICU study, which investigates biomarkers for diagnosis of hemophagocytic lymphohistiocytosis (HLH) in critically ill patients.

Research interests:

  • Hemophagocytic Lymphohistiocytosis (HLH)
  • Immune function und immune modulatory treatments in critically ill patients


Dr. Gunnar Lachmann
Gunnar Lachmann

Ignacio Martín-Loeches, MD PhD

Ignacio Martin-Loeches, MD, PhD, EMBA (IESE), FJFICMI is a full time Consultant in Intensive Care Medicine, Senior Clinical Lecturer & Research Director of the Multidisciplinary Intensive Care Research Organization (MICRO) at Trinity College, Dublin. Currently Vice-Chair of Intensive Care Medicine at St James’s University Hospital, Dublin.

He is the Chair of the Severe Sepsis and Septic Shock Working Group “4SWG”, Steering committee member for the Surviving Sepsis Campaign and Chair for CoBaTrICE at the ESICM.

He is the currently member of the Clinical Trials of Health Research Board in Ireland. He is the Principal Investigator of European Regional Development Funds (ERDF) grants and the European Network for ICU-related respiratory infections (ENIRRIs) under the European Respiratory Society (ERS). He serves as section Editor at the Intensive Care Medicine (ICM) Journal.

Ignacio Martín-Loeches, MD PhD
Ignacio Martín-Loeches

Prof. Guillaume Monneret, MD PhD

He is Professor of Immunology and Head of Clinical Immunology Laboratory at Lyon University Hospitals (France). He leads a research group (EA7426, Claude Bernard University, Lyon, F) entitled “pathophysiology of injury-induced immunosuppression” - part of this group is a joint unit with bioMérieux dedicated to biomarkers from transcriptomic approach. 

Overall research focuses are: ICU-acquired immunosuppression (mechanisms, monitoring), immunotherapy in sepsis (e.g., IL-7) and standardized use of clinical flow cytometry.

Prof. Guillaume Monneret
Guillaume Monneret

Axel Nierhaus MD, EDIC

Axel Nierhaus is a senior consultant intensivist at the Department of Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Germany. His department is one of the largest in the country, with 140 ICU beds and more than 8.500 adult patients per year.

As a clinician-scientist, he is mainly interested in developing, testing and validating novel methods for real-life diagnosis of both innate and adaptive immune responses in patients with sepsis and septic shock. EGIS certainly is a unique platform for this.

Axel Nierhaus
Axel Nierhaus

Marcin Osuchowski, DVM PhD

Marcin Osuchowski, DVM, PhD, is a head of Intensive Medicine at the Ludwig Boltzmann Institute for Experimental and Clinical Traumatology in Vienna, Austria. Dr. Osuchowski is a recipient of Fulbright fellowship (2000), the Best Young Investigator in Shock Research (2006) and Austrian Champion in European Research (2008). He is a coordinator for the Wiggers-Bernard Expert Consensus Initiative for Improvement of Animal Modeling in Sepsis (LBI Trauma/AUVA), co-coordinator (with DG Remick) of the Sepsis Model Scoring Taskforce (Shock Society) and currently  serves as treasurer for the European Shock Society.

Research interests:

  • Pathophysiological mechanisms and prevention of early and late mortality in sepsis and trauma/hemorrhage.
  • Targeted therapeutic interventions modulating the genomic/humoral/cellular signaling including the role of age/gender in sepsis pathophysiology
  • Development and application of clinically-relevant animal models of sepsis.
Marcin Osuchowski
Marcin Osuchowski

Prof. Joerg C. Schefold MD

  • Author of the first randomized controlled clinical trial on immunostimulation in sepsis using an immune-biomarker guided personalized approach.
  • Key research interest: development and testing of novel immunomodulatory interventional therapeutical strategies (incl. efficacy and safety).
  • Link between the immune system and metabolism in sepsis (e.g. IDO expression)


Joerg C. Schefold MD PhD
Joerg C. Schefold

Manu Shankar-Hari, MSc PhD

He is clinician-scientist in Intensive Care Medicine, and group lead for a translational research group at King’s College London. Manu is currently funded by a prestigious UK NIHR Clinician Scientist Award.

The research programme that he leads on includes:

  • The epidemiology and adaptive immune system changes to identify ways to improve acute and longer-term outcomes in adult critically ill patients with sepsis.
  • Identifying homogenous groups with extreme clinical or biological or outcome characteristics (extreme phenotypes) to inform future trial design in ARDS and sepsis.

For further details; please see:

Manu Shankar-Hari
Manu Shankar-Hari

Tomasz Skirecki, MD PhD

Head of the Laboratory of Flow Cytometry at Centre of Medical Postgraduate Education in Warsaw, Councillor of the European Shock Society, PI of the Polish National Science Center grants.

Main research interest: role of immunity in organ dysfunction in sepsis, recovery of immune system after sepsis, animal models of sepsis


Tomek Skirecki
Tomasz Skirecki

Dr. Antoni Torres

  • Co-ordinator of the ENIRRI netowork for the Study of Respiratory Infections in ICU.
  • Chairman of the International Guidelines for HAP/VAP (Eur Respir J 2017) and co-chairman of the International Guidelines for severe CAP.
  • Main research interest: Immune responses in CAP and HAP.


Antoni Torres
Antoni Torres

Dr. Florian Uhle

As a biologist by training and translational medical scientist by passion, Dr. Uhle currently works as a research group leader at the Department of Anesthesiology of the Heidelberg University Hospital. His interdisciplinary team, consisting of biologists, physicians and bioinformaticians, strives to expand the mechanistic understanding of post-acute and long-term consequences of severe systemic inflammation on the host’s immune system. In this context, the group is also working on the identification and implementation of novel cellular and host-response biomarkers of infection and immunosuppression to inform clinical decision-making in the ICU.

Acknowledging progress as a combined effort, he fully supports the unifying goal of EGIS to close current gaps in the knowledge about sepsis, ultimately aiming to improve therapy.

Dr. Florian Uhle
Florian Uhle

Prof. Tom Van der Poll, MD, PhD

He is Professor of Medicine and Chair of the Department of Medicine in the Amsterdam University Medical Centers, location Academic Medical Center, University of Amsterdam, the Netherlands. Van der Poll is board certified in Internal Medicine and Infectious Diseases. He is past Chair and current council member of the International Sepsis Forum. Van der Poll’s research focuses on pneumonia and sepsis, particularly on pathogenesis, the host response, immunotherapy and biomarkers.

Tom van der Poll
Tom van der Poll

Prof. Fabienne Venet

Professor of Immunology at Lyon-Est Medical School (Claude Bernard Lyon I University, Lyon, F), Fabienne Venet is leading a research team focused on the study of mechanisms leading to injury-acquired immunodeficiency within Prof G. Monneret’s research group “Pathophysiology of injury-induced immunosuppression” (EA7426, Claude Bernard University, Lyon, F).


Fabienne Venet
Fabienne Venet

Prof. Dr. Markus Weigand

Prof. Markus Weigand is a board-certified anesthesiologist and head of the Department of Anesthesiology, Heidelberg University Hospital. He is currently chairman of the German Sepsis Society. He received extensive training on basic immunology during fellowships at world-renowned research institutions, including the German Cancer Research Center in Heidelberg and the Basel Institute of Immunology, which shaped his scientific profile and interest in translational immunology. His research focus now lies in the translation of basic research into the clinic, especially the application of precision therapy for the treatment of immune dysfunction in the context of nosocomial and opportunistic infections.


Prof. Dr. Markus Weigand
Markus Weigand

Prof. W. Joot Wiersinga, MD, PhD

He is chair of the Division of Infectious Diseases of the Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands. He currently chairs the European Sepsis Academy and is on the executive committee of the ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis – (ESGBIES) as well council member of the International Sepsis Forum (ISF). In addition he currently chairs the Infection group of the Surviving Sepsis Campaign guideline committee.

Focus of research: Host-pathogen interactions and innate immune responses in infectious diseases

Special interest in: sepsis, pneumonia, cellulitis, melioidosis, optimisation of antibiotic treatment and the gut microbiome.

For further details; please see:

Professor W. Joot Wiersinga, MD, PhD
W. Joot Wiersinga

Martin Sebastian Winkler, MD

Martin Winkler is currently working as a consultant at the Department of Anesthesiology and Intensive Care Medicine, University of Göttingen. Martin is interested in bench-to-bedside methods of immune monitoring in ICU and sepsis. Martin supports EGIS as an inspiring cross-border platform to create new ideas and methods.


Martin Sebastian Winkler
Martin Sebastian Winkler